Up-regulation of $\alpha_1$-adrenoceptors on cutaneous nerve fibres after partial sciatic nerve ligation and in complex regional pain syndrome type II

Peter D. Drummond, Eleanor S. Drummond, Linda F. Dawson, Vanessa Mitchell, Philip M. Finch, Christopher W. Vaughan, Jacqueline K. Phillips

PII: S0304-3959(13)00669-6
DOI: http://dx.doi.org/10.1016/j.pain.2013.12.021
Reference: PAIN 9076

To appear in: PAIN

Received Date: 26 August 2013
Revised Date: 7 December 2013
Accepted Date: 10 December 2013

Please cite this article as: P.D. Drummond, E.S. Drummond, L.F. Dawson, V. Mitchell, P.M. Finch, C.W. Vaughan, J.K. Phillips, Up-regulation of $\alpha_1$-adrenoceptors on cutaneous nerve fibres after partial sciatic nerve ligation and in complex regional pain syndrome type II, PAIN (2013), doi: http://dx.doi.org/10.1016/j.pain.2013.12.021

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Up-regulation of $\alpha_1$-adrenoceptors on cutaneous nerve fibres after partial sciatic nerve ligation and in complex regional pain syndrome type II

Peter D. Drummond, a Eleanor S. Drummond, a Linda F. Dawson, a Vanessa Mitchell, b Philip M. Finch, a
Christopher W. Vaughan, b Jacqueline K. Phillips, c

a Centre for Research on Chronic Pain and Inflammatory Diseases, Murdoch University, Perth, Western Australia; b Pain Management Research Institute, Kolling Institute, Northern Clinical School, The University of Sydney, NSW, Australia; c Australian School of Advanced Medicine, Macquarie University, Sydney, NSW, Australia

Address for correspondence: Professor Peter Drummond, School of Psychology and Exercise Science, Murdoch University, 6150 Western Australia. Ph: 61-8-93602415. Fax: 61-8-93606492. Email: P.Drummond@murdoch.edu.au
Key words: $\alpha_1$-adrenoceptors; up-regulation; partial sciatic nerve lesion; complex regional pain syndrome; immunohistochemistry
Introduction

After peripheral nerve injury, nociceptive afferents acquire an abnormal excitability to adrenergic agents that is linked with behavioural signs of pain [3; 11; 25; 26; 31; 34; 44]. Likewise, in chronic pain states such as post-herpetic neuralgia, cutaneous neuromas, amputation stump pain and complex regional pain syndrome (CRPS), intradermal administration of $\alpha_1$-adrenoceptor ($\alpha_1$-AR) agonists into affected sites may evoke aberrant pain that can persist for 30-60 minutes [2; 7-9; 27; 29; 51].

Within the central nervous system, quantitative radioligand binding studies in animal models have demonstrated an increased neural expression of $\alpha_1$-ARs on surviving neurons after spinal transection or chemical lesion of adrenergic neurons [16; 37; 43]. Similarly, within the peripheral nervous system, messenger RNA for the $\alpha_{1B}$-AR increased in rat dorsal root ganglia following peripheral nerve section or ligation of spinal nerves supplying those ganglia [31; 57]. Importantly, the proportion of dorsal root ganglion neurons that responded to norepinephrine increased markedly after nerve injury induced by loose or tight ligation of the sciatic nerve [39]. Conversely, the $\alpha_1$-AR antagonist prazosin inhibited nociceptive fibre discharge in neuropathic pain models when given systemically [20; 23; 34]. Together, these findings suggest that an increased neural expression of $\alpha_1$-ARs after peripheral nerve injury increases the excitability of nociceptive afferents.

We recently used immunohistochemistry to identify $\alpha_1$-ARs on nociceptive fibres in normal rat skin [10], but whether $\alpha_1$-AR expression changes on these nerve fibres after peripheral nerve injury is unknown. Hence, the aim of this study was to determine whether neural expression of $\alpha_1$-ARs increased in the skin after partial sciatic nerve ligation (PSL) in rats, and in CRPS following a peripheral nerve injury in humans (causalgia or CRPS type II). PSL is a well-characterized model of CRPS type II associated with allodynia to light touch and hyperalgesia to noxious mechanical and thermal stimuli [45-47]. These pain behaviours are suppressed by intraperitoneal injection of
guanethidine, an agent that displaces norepinephrine from sympathetic adrenergic neurons [30; 47].

Involvement of the sympathetic nervous system in CRPS is controversial [6]; nevertheless, adrenergic agonists aggravate pain in a subpopulation of CRPS patients [2; 9; 29; 51], and many patients with CRPS type II report long-term benefits after sympathectomy of the affected limb [5; 18]. Thus, we hypothesized that $\alpha_1$-AR expression would increase on nerve fibres in the skin and sciatic nerve trunk after PSL in rats, and on nerve fibres in the skin of humans with CRPS type II.

**Methods**

**Animals and surgery**

Experiments were approved by the Murdoch University and Royal North Shore Hospital Animal Care and Ethics Committees. Tissues were obtained from 6 – 8 week old Wistar rats obtained from Animal Resources Centre (Canning Vale, Australia), following the guidelines of the ‘NH&MRC Code of Practice for the Care and Use of Animals in Research in Australia’. Animals were housed in groups of three in individually ventilated cages under a 12-12 hour light-dark cycle, with environmental enrichment and free access to water and standard rat chow. The PSL model of nerve injury was performed using the method outlined by Seltzer et al. [45]. Briefly, the left sciatic nerve was exposed at mid-thigh level and a 4–0 silk suture inserted into the nerve to tightly ligate the dorsal 1/3 - 1/2 of the nerve trunk approximately 3 mm proximal to the trifurcation of the sciatic nerve [22]. The muscle (4–0) and then the skin (3–0) were closed with silk sutures. Sham-operated animals underwent the same surgery as the PSL-operated animals except that sutures were not inserted into the nerve and the nerve was not ligated. Six animals were examined in each experimental group. Mechanical allodynia was assessed prior to surgery (baseline) and again prior to perfusion either 4 or 28 days post-surgery in all animals using a series of Von Frey hairs to test the paw withdrawal threshold (range 0.2 g to 15 g) using the up-down paradigm outlined by Jayammane et al. [22]. Animals were tested in batches of four mixed sham/PSL animals and the experimenter was blinded to the operation type.
Tissue processing and immunohistochemistry

Rats were heavily anesthetized with an intraperitoneal injection of sodium pentobarbitone (100mg/kg, Thiobarb, Jurox Pty. Ltd, NSW, Australia). Each rat was transcardially perfused with heparinized saline (0.2% v/v heparin, Mayne Pharma Pty Ltd, Melbourne, Australia and 0.9% w/v NaCl₂, pH 7.4) followed by 4% v/v formalin in 0.9% w/v NaCl₂, pH 7.3). The feet were then removed and postfixed in the 4% formalin solution for 4 hrs at room temperature. Plantar and hairy skin was collected from each hind paw, and then washed in 0.1M Phosphate Buffer (PB, pH 7.4) for 30 min, dehydrated in 50% v/v ethanol for 30 min and washed twice in PB for 15 min each. Tissues were cryoprotected by incubation for 48 hours in 30% w/v sucrose dissolved in tris phosphate buffered saline (TPBS, 0.1M PB, 0.9% w/v NaCl₂, 1% w/v tris base, pH 7.4) containing 0.1% w/v sodium azide (NaN₃) and then mounted in TissueTek® OCT compound (Sakura Finetek, Zoeterwoude, The Netherlands) and stored at -80°C until use. 10 µm thick cryosections were cut using a cryostat (Leica CM 1850 UV, Nussloch, Germany) and collected onto silane coated slides (Hurst Scientific) and stored at -20°C until use.

Samples of the lesioned sciatic nerve were collected from four PSL animals four days after surgery and four sham operated animals at the same time point. Tissues were processed as described above.

For immunohistochemistry, sections were initially washed in 0.1M PBS (3x10 min) and incubated with 0.2% triton X-100 in PBS for 7.5 min at room temperature. Sections were washed with PBS (3x5 min) and blocked for 2 hrs in 10% donkey serum (Sigma) in PBS at room temperature. Sections were then treated with the following combinations of primary antibodies: α₁-AR/calcitonin gene related peptide (CGRP)/pan neuronal marker (TUJ1) to examine α₁-AR expression on peptidergic afferent nerve fibres; α₁-AR/ isolectin B4 (IB4)/TUJ1 to examine α₁-AR expression on non-peptidergic afferent nerve fibres; α₁-AR/ neurofilament 200 (NF200)/TUJ1 to examine α₁-AR expression on myelinated fibres; α₁-AR/ smooth muscle actin to examine α₁-AR expression on blood vessel walls; and myelin basic protein (MBP)/ NF200/α₁-AR to determine whether α₁-ARs were expressed on NF200⁺ axons or
co-localised with the myelin sheath surrounding these axons (details and dilutions are shown in Table 1). Antibodies were co-incubated for 48 hrs at 4°C, diluted in blocking solution. Sections were then washed with PBS (3x15 min) and incubated with the appropriate species specific secondary antibodies (Table 1) diluted in 5% donkey serum (Sigma) in PBS for 4 hrs at room temperature. Sections were washed with PBS (3x15 min) and coverslipped with Prolong Gold anti-fade mounting media (Invitrogen). The pattern of staining produced by the α₁-AR antibody on blood vessels, nerves and keratinocytes resembles the staining pattern produced by BODIPY FL-prazosin, a fluorescent α₁-AR antagonist [10]. In addition, staining is eliminated following pre-adsorption of the anti-sera with an α₁-AR-specific peptide [10], and the peptide sequence recognized by the α₁-AR antibody is not found in any other G-protein-coupled receptor or non-receptor protein (National Center for Biotechnology Information, National Institutes of Health, BLAST program, http://blast.ncbi.nlm.nih.gov/Blast.cgi). A representative example of α₁-AR expression on the smooth muscle cells of large and small blood vessels is shown in supplementary Figure e1. Two consecutive sections per sample were stained and all immunohistochemistry for each staining combination was performed at the same time to ensure staining consistency. No staining was observed on negative control sections that had all primary antibodies omitted.

**Human tissue processing and immunohistochemistry**

Each participant provided written informed consent for the procedures, which were approved by the Human Research Ethics Committee at Murdoch University. Skin biopsies were collected from two women and three men aged between 23 and 56 years who met the clinical criteria for CRPS type II [32] (Table 2). The syndrome had begun 6 months to 10 years previously after accidental laceration of the ulnar nerve (two cases), surgery involving the sural or median nerve (two cases) or a crush injury of the sciatic nerve (one case). In each case, the injury was associated with a region of diminished sensation; however, pain and other sensory, autonomic and motor symptoms had spread beyond the distribution of the injured nerve. Pain decreased after sympathetic blockade in one patient but did not change in two other cases. Skin biopsies were collected under sterile
conditions using a 3 mm diameter skin biopsy punch under local anaesthesia. Two biopsies were collected per patient; one from a region of hyperalgesia and another from the mirror image site on the contralateral limb. For comparison, skin samples were also collected from the dorsolateral aspect of one hand in four women and six men aged between 24 and 68 years (mean age 46 ± 15 years) without chronic pain.

The biopsies were fixed in Zamboni’s solution (5% formalin and 1% picric acid in 0.9% saline) for 4 hours at 4°C, washed in PBS, incubated in 50% ethanol for 30 min followed by a further two rinses in PBS prior to paraffin embedding and sectioning into 10 μm sections that were collected onto silane coated slides (Hurst Scientific).

Sections were double-labelled for the α₁-AR and pan neuronal marker Protein Gene Product-9.5 (PGP9.5) using immunohistochemistry. As antibodies for each of these labels were raised in rabbit, the immunohistochemistry protocol was combined with tyramide signal amplification, which allows differentiation between two primary antibodies raised in the same species. Sections were deparaffinised through xylene and a descending series of ethanol washes to 0.1M PBS. Antigen retrieval was performed by incubation with 1mg/mL porcine trypsin (Sigma-Aldrich) for 20 min at 37°C. Sections were incubated with 3% H₂O₂ in PBS for 10 min to quench endogenous peroxidase activity, and then treated with 0.2% Triton X-100 in PBS for 5 min prior to incubation with blocking solution containing 10% normal donkey serum in PBS for 2 hrs. Next, sections were incubated with anti-PGP9.5 diluted 1:400,000 in blocking solution overnight at room temperature (rabbit anti-PGP9.5; AbD Serotec, USA, Product code 7863-0504), followed by biotin conjugated donkey anti-rabbit IgG for 1 hr (1:000; Jackson ImmunoResearch), streptavidin-horse radish peroxidase (1:150) for 30 min and biotin-conjugated tyramide (1:100 in amplification solution; Tyramide Signal Amplification Kit, NEL700; Perkin-Elmer Life Sciences) for 3 min. Sections were then incubated with Dylight 549-conjugated streptavidin (1:1000; Jackson ImmunoResearch) for 1 hr. Sequential double labelling was completed by incubation with rabbit anti-α₁-AR (1:250) diluted in blocking solution for
48hrs at 4°C followed by anti-rabbit DyLight-488 conjugated secondary antibody (1:600; Jackson ImmunoResearch) diluted in PBS for 4 hrs at room temperature. Sections were coverslipped with Prolong Gold.

**Imaging and quantification of immunohistochemistry**

Images of immunostained sections were collected using a Leica TCS SP2 multiphoton confocal microscope by an investigator who was blinded to side and group (PSL/sham and patient/control). Each label was collected sequentially at the appropriate excitation and emission spectra. For sciatic nerve sections, single images were acquired under 400x magnification, stacking a series of optical sections (Z-series) acquired at 1 µm intervals throughout the depth of the tissue. Skin sections were examined under 200X magnification with each z-series image collected every 2 µm. Two images, one of the papillary dermis containing the epidermis and the dermal nerve fibres, and one of the reticular dermis containing the large dermal nerve bundles, were collected for each skin section. Quantification was subsequently performed using the maximum projection image of the resulting stack. Care was taken to ensure that there was no bleed-through between channels using the imaging settings chosen, and all imaging settings were consistent for all sections in each staining run.

Both in rat and human skin samples, α₁-AR staining intensity was quantified in the epidermis, blood vessels, nerve fibres in the dermis and nerve fibres in large dermal nerve bundles by a blinded investigator. The epidermis was identified by morphology, blood vessels by smooth muscle actin, and nerve bundles and fibres in the dermis by pan-neuronal markers (TUJ1 for rat tissue and PGP9.5 for human tissue). In sections of rat sciatic nerve, α₁-AR staining intensity was quantified in axons, which were identified by TUJ1 staining. α₁-AR staining intensity in each region was quantified in at least two sections from each sample and averaged.

Quantification of α₁-AR staining intensity was performed using ImageJ software (Image J, version 1.47t, National Institute of Health, USA). To determine average pixel intensity on individual nerve fibres in the dermis or within nerve bundles, TUJ1 or PGP9.5 staining was used to create a mask of
nerve fibre location, which was then applied to the corresponding α₁-AR stained image. This ensured that α₁-AR expression was only examined in those pixels also positive for TUJ1 or PGP9.5 staining. A similar approach was employed to quantify vascular α₁-ARs using smooth muscle actin to create a mask of blood vessel location. Quantification of α₁-AR intensity in the keratinocyte layer of the epidermis was performed by manually drawing around the keratinocyte layer and measuring the average α₁-AR intensity in the defined region.

α₁-AR staining intensity in rat tissue was also quantified in specific neuronal populations; peptidergic CGRP⁺ neurons, non-peptidergic IB4⁺ neurons, and myelinated NF200⁺ neurons. For this quantification, a co-localisation analysis using the “Colocalization Finder” plugin for ImageJ was performed between each of these specific neuronal markers and TUJ1. This analysis allowed identification of all pixels that were immuno-positive for TUJ1 and individual neuronal markers, ensuring that all regions included in the resulting mask were these nerve fibres. This mask was then applied to the corresponding α₁-AR image and α₁-AR staining intensity was quantified in these neuronal populations.

**Statistical approach**

To combine data for neural markers across multiple immunohistochemistry runs, α₁-AR staining intensity within each run was expressed in normalized units for each region of interest (the keratinocyte layer of the epidermis, dermal blood vessels, nerve fibres in the papillary dermis, and nerve bundles in the reticular dermis). Raw scores from the ipsilateral and contralateral sides in lesioned and sham animals were combined into a single variable for each run and region, and transformed into scores with a mean of 0 and a standard deviation of 1 (i.e., Z-scores). Hence, positive scores represented greater than average α₁-AR staining intensity, whereas negative scores represented less than average α₁-AR staining intensity. These normalized scores were averaged across multiple immunohistochemistry runs for each animal to obtain a mean score for each region of interest. As the distribution and intensity of α₁-AR expression was similar in the plantar and hairy
skin, these data were also averaged for quantification purposes. Mean scores were then compared between the injured and contralateral limb with Wilcoxon’s matched-pairs signed-ranks tests, and between experimental and control groups with Mann-Whitney U tests. A similar approach was used to investigate differences in $\alpha_1$-AR staining intensity in patients with CRPS Type II versus controls. Results are reported as the mean ± standard error, and the criterion of statistical significance was p<0.05.

Results

Mechanical allodynia after PSL

Prior to surgery all animals had a paw withdrawal threshold of 15 g. Paw withdrawal threshold in the ipsilateral limb was reduced to 0.4 ± 0.2 g at 4 days after PSL surgery and to 0.2 ± 0.1 g at 28 days after PSL. Paw withdrawal threshold was unchanged from baseline levels in all animals that underwent sham surgery.

$\alpha_1$-AR expression in the skin after PSL

The strongest expression of $\alpha_1$-ARs in the skin was observed in the epidermis. Strong $\alpha_1$-AR expression was also observed in hair follicles, blood vessels and nerves, consistent with findings from our previous study [10]. This pattern of expression did not change in vascular or epidermal cells either 4 or 28 days after PSL.

PSL resulted in an up-regulation of $\alpha_1$-ARs on papillary dermal nerve fibres identified by the pan-neuronal marker TUJ1. At 4 days after surgery, $\alpha_1$-AR expression was significantly greater on nerve fibres in skin ipsilateral to injury than in animals that underwent sham surgery (p = .015) (Figure 1A). The intensity of $\alpha_1$-AR expression in individual sensory nerve populations was then quantified to determine whether the up-regulation of $\alpha_1$-AR expression was associated with specific nerve population(s). $\alpha_1$-AR expression was significantly greater in non-peptidergic IB4$^+$ nerve fibres at 4 days post-PSL in comparison to animals that underwent sham surgery (p = .032), while $\alpha_1$-AR expression was not significantly altered on peptidergic CGRP$^+$ nerve fibres or myelinated NF200$^+$
nerve fibres in the papillary dermis (Figure 1A). $\alpha_1$-AR expression was no longer up-regulated on papillary dermal nerve fibres at 28 days after PSL (Figure 1B).

The intensity of $\alpha_1$-AR expression was also quantified on axons in large nerve bundles in the deeper dermis. $\alpha_1$-AR expression was significantly elevated in TUJ1$^+$ axons in skin ipsilateral to PSL at 4 days post-surgery in comparison to sham animals ($p = .015$) (Figure 1C). Specific, individual axons within nerve bundles were observed to have particularly high expression of $\alpha_1$-AR after PSL (Figure 2), which was localized on axons and not in the surrounding connective tissue (Figure 2C). When $\alpha_1$-AR expression in individual nerve populations was examined, it was found that $\alpha_1$-AR staining intensity was significantly higher in IB4$^+$ axons at 4 days after surgery in skin ipsilateral to PSL in comparison to animals that underwent sham surgery ($p = .017$), although this was due largely to an outlier in the PSL group (Figure 1C). As shown in Figure 3, $\alpha_1$-AR staining intensity within NF200$^+$ axons was also found to be significantly higher in skin ipsilateral than contralateral to PSL at 4 days after surgery ($p = .028$), and higher ipsilateral to PSL than in sham animals ($p = .041$) (Figure 1C). There was also a trend for higher $\alpha_1$-AR expression in CGRP$^+$ axons after PSL in comparison to animals that underwent sham surgery, but with high variation among animals.

The up-regulation of $\alpha_1$-AR expression on axons in larger nerve bundles persisted at 28 days after PSL. $\alpha_1$-AR expression on TUJ1$^+$ axons remained significantly higher in skin ipsilateral to PSL in comparison to that from animals that underwent sham surgery ($p = .009$) (Figure 1D). $\alpha_1$-AR staining intensity in skin ipsilateral to PSL remained significantly higher in NF200$^+$ axons in comparison to those from skin contralateral to PSL ($p = .009$) and from animals that underwent sham surgery ($p = .028$) (Figure 1D).

Co-localisation analysis for MBP, NF200 and $\alpha_1$-AR revealed that the vast majority of $\alpha_1$-AR staining co-localised with NF200, while there was minimal co-localisation with MBP (Figure 4). As NF200 stains intracellular neurofilaments in nerve fibres, this suggests that $\alpha_1$-AR was up-regulated on axons and not in the surrounding myelin sheath.
**α₁-AR expression in the sciatic nerve after PSL**

α₁-AR was expressed on many axons within the sciatic nerve. Four days after PSL, α₁-AR expression further increased in IB4⁺ neurons in comparison to surrounding axons that did not express IB4 (Figure 5), being 92 ±15% greater in IB4⁺ neurons than in the non-IB4⁺ surrounding axons 4 days after PSL surgery compared with 43 ±7% greater in IB4⁺ neurons than in the surrounding non-IB4 axons 4 days after sham surgery (p = .043). This up-regulation was specific to IB4⁺ axons as there were no significant differences in α₁-AR expression on axons in the sciatic nerve labelled with CGRP or NF200 between the PSL and sham groups.

**α₁-AR expression in the skin of patients with CRPS type II**

α₁-AR expression on nerve fibres in the dermis was greater in CRPS-affected limbs than in controls (p = .001) and, in each case, was greater in the CRPS-affected than unaffected limb of patients with CRPS type II (Figure 6A and Figure 7). Similarly, α₁-AR expression within the epidermis was greater in CRPS-affected limbs than in controls (p = .038) (Figure 6B and Figure 8). However, α₁-AR expression on blood vessels was similar in patients and controls. In the group as a whole, α₁-AR expression on dermal nerve fibres and keratinocytes did not differ significantly between the unaffected limb of patients with CRPS type II and controls (Figure 6).

**Discussion**

The aim of this study was to determine whether α₁-AR expression was up-regulated on nerve fibres in the skin in an animal model of CRPS type II and in patients with this condition. Four days after PSL, α₁-ARs were expressed more strongly on nerve fibres that survived the injury than on nerve fibres in animals that underwent sham surgery. This heightened α₁-AR expression was observed on non-peptidergic nociceptive afferents labelled with IB4 in the injured sciatic nerve, in dermal nerve bundles, and in the terminal distribution of these nerve fibres. Heightened expression of α₁-AR was also associated with NF200, a marker of myelinated nerve fibres, in dermal nerve bundles both 4 and 28 days after PSL. Co-localisation studies indicated that α₁-ARs were expressed on axons rather than
on surrounding myelin or connective tissue. Furthermore, α1-ARs were expressed more strongly on nerve fibres in affected than unaffected skin in patients with CRPS type II and also more strongly than that seen in the skin of pain-free controls. Together, these findings provide compelling evidence of an up-regulation of α1-ARs on cutaneous nociceptive afferents after peripheral nerve injury. As each of the nerve fibre types that expressed α1-ARs after nerve injury also express α1-ARs in the uninjured state [10], this up-regulation appeared to involve heightened production of α1-ARs rather than expression on nerve fibres that did not previously produce α1-ARs.

Four days after sciatic nerve injury, α1-ARs were up-regulated on IB4+ nerve fibres. These non-peptidergic unmyelinated nerve fibres form a dense intra-epidermal network that protects the organism from potential harm by detecting noxious stimuli at the interface with the external environment [49]. This up-regulation was also detected in the sciatic nerve trunk, possibly due to increased axonal transport of α1-ARs from production points in the soma or heightened membrane expression of α1-ARs along the length of the unmyelinated nerve fibres.

Up to 28 days after nerve injury, up-regulation of α1-AR expression was also observed on NF200+ nerve fibres in dermal nerve bundles, but this did not extend to the sciatic nerve trunk or the papillary dermis. After peripheral nerve injury, NF200 is retained in only a small population of nerve fibres in the papillary dermis [38]. Thus, our findings suggest that α1-AR expression was up-regulated on NF200+ nerve fibres that lost NF200 in the papillary dermis, or that did not retain their superficial extensions after nerve injury. NF200 identifies medium- and large-diameter myelinated neurons, including A-delta nociceptors that express the tyrosine receptor kinase A (TrkA), a high-affinity receptor for nerve growth factor [4]. Many large-diameter nerve fibres that contain neurofilaments apparently lose their myelin before terminating in the skin [10; 41] and other peripheral tissues [19] (notably, most NF200+ nerve fibres within the dermal nerve bundle shown in Figure 4B were unmyelinated). It would be interesting to determine whether α1-ARs are expressed preferentially at nodal sites in myelinated axons, as this might explain why heightened co-localisation between α1-AR
and NF200 was limited to unmyelinated axons in dermal nerve bundles after PSL whereas $\alpha_1$-AR expression was increased on unmyelinated IB4$^+$ fibres both in dermal nerve bundles and more proximally in the sciatic nerve.

Peripheral nerve injury evokes a complex response involving Wallerian degeneration, modifications in the phenotype of surviving neurons, neural regeneration and collateral sprouting. For example, a subpopulation of myelinated A-beta fibres that normally signal touch undergoes a phenotypic switch that involves increased expression of certain ion channels and membrane receptors [54], and an enhanced synthesis of nociceptive neurotransmitters such as substance P and CGRP [35]. This local response evokes changes in afferent signalling that result in central sensitisation, cortical remodelling and alterations in descending pain modulation processes [55; 58]. Wallerian degeneration is associated with an influx of immune cells into damaged nerves which, together with damaged axons, resident Schwann cells and target tissues, release inflammatory mediators and neurotrophins that reduce the firing threshold and induce transcriptional changes in production of neuropeptides, ion channels and membrane receptors in surviving neurons [14; 50; 55].

Neurotrophins such as nerve growth factor might trigger the synthesis of $\alpha_1$-AR, as nerve growth factor augments the production of $\alpha_{1A}$-AR in cultured dorsal root ganglion cells and increases their responsiveness to norepinephrine via actions on $\alpha_1$-ARs [61]. In turn, heightened $\alpha_1$-AR expression could augment neuroinflammatory responses by enhancing the release of inflammatory mediators such as substance P and prostaglandin E$_2$ [12; 24; 52]. Following partial peripheral nerve injury, sympathetic adrenergic fibres sprout in close proximity to nociceptive fibres, likely due to increased levels of nerve growth factor [28; 59]. The apposition of these two fibre types might permit aberrant crosstalk due to adrenergic excitation of up-regulated $\alpha_1$-ARs on nociceptive fibres. $\alpha_1$-AR activation generally increases neural excitability [17; 36; 40]; hence, stimulation of up-regulated $\alpha_1$-ARs both on resident nociceptors and on myelinated afferents with de novo nociceptive properties could augment pain.
In a radioligand binding study, we previously found that \( \alpha_1 \)-AR density was greater in CRPS-affected skin than in the skin of normal controls [13], but the cellular source of this up-regulation could not be determined. The present findings suggest that cutaneous nerve fibres are an important source of heightened \( \alpha_1 \)-AR expression in the skin of patients with CRPS type II; however, the chief source might be keratinocytes, as \( \alpha_1 \)-AR expression was most intense in the epidermis, particularly on the affected side in patients with CRPS type II. The effect of this \( \alpha_1 \)-AR up-regulation on keratinocyte function is uncertain, but it is interesting that an elevated sodium channel expression in the keratinocytes of patients with CRPS type I may increase their excitability [62]. Keratinocytes are a major source of cutaneous nerve growth factor which, after peripheral nerve injury, can stimulate hyperexcitability in regenerating afferent nerve fibres [42]. Thus, in the presence of adrenergic agonists such as epinephrine or norepinephrine, liberation of inflammatory mediators or growth factors from hyperexcitable keratinocytes might contribute to pain. However, this speculation will have to be confirmed in further studies.

In contrast to patients with CRPS type II, \( \alpha_1 \)-AR expression was not altered on keratinocytes in the injured limb of rats after PSL. The basis of this discrepancy is unclear, but might involve differences in timing (4-28 days after injury in rats compared with months or years after peripheral nerve injury in patients with CRPS type II), variation in the location or extent of injury between the animal model and the human condition, or differences in the intensity of the neuroinflammatory response that might trigger \( \alpha_1 \)-AR up-regulation. In addition, heightened expression of \( \alpha_1 \)-ARs on dermal nerve fibres was detected in CRPS patients many months after peripheral nerve injury, but had resolved in the papillary dermis within 28 days of PSL in the rodent model. Whether this represents a species difference or a characteristic of CRPS is unknown.

Vascular sensitivity to vasoconstrictor agents, including \( \alpha_1 \)-AR agonists, increases after nerve injury [53; 60]. Nevertheless, in the present study, vascular expression of \( \alpha_1 \)-ARs did not change after PSL, and was similar in patients with CRPS type II and controls. Loss of neuronal noradrenaline
transporters or other changes (e.g., in gap-junction proteins, angiotensin II receptor expression or intracellular signalling to contractile stimuli) may contribute to denervation supersensitivity [53]. Alterations in circulatory dynamics resulting from this nonspecific increase in vascular sensitivity could augment inflammation and/or pain [56].

Overall, our results indicate that $\alpha_1$-AR expression increases on keratinocytes and nociceptive afferents after peripheral nerve injury both in a well-characterized animal model of CRPS type II and in the human condition. Only one of three patients in this small series clearly benefited from regional sympathetic blockade, and none had been treated with adrenergic blocking agents. Nevertheless, in uncontrolled trials, non-specific $\alpha$-adrenergic antagonists such as phentolamine and phenoxybenzamine [15; 21; 33] and specific $\alpha_1$-AR antagonists such as prazosin and terazosin decreased the pain of CRPS [1; 48]. The present findings establish a mechanistic basis for this therapeutic effect in patients with CRPS type II. In particular, $\alpha_1$-antagonists may block the actions of circulating or locally secreted catecholamines on neural $\alpha_1$-ARs, or prevent the adrenergic activation of keratinocytes. Thus, further exploration of the therapeutic potential of $\alpha_1$-blockers for CRPS type II seems warranted.
Acknowledgements

The authors would like to acknowledge Ms Gael Gibbs and Dr Niloufer Johannsen for technical assistance in the development of the immunohistochemistry protocol, and the scientific and technical assistance of the Australian Microscopy & Microanalysis Research Facility at the Centre for Microscopy, Characterisation & Analysis, University of Western Australia. This work was supported by grants from the National Health and Medical Research Council of Australia (grant numbers APP1030379, 437205); the Australian and New Zealand College of Anaesthetists (grant number 12/024); Hillcrest Foundation (Perpetual grants A11/00067 and FR2012/1078) and unrestricted grants from Pfizer, Medtronic Australasia and St Jude Medical.

Conflicts of interest statement

None of the authors has a conflict of interest with the contents of this paper.
References


Figure legends

Supplementary Figure e1: $\alpha_1$-AR expression (red) on the smooth muscle cells (green) of a large artery in cross-section and a small blood vessel cut longitudinally (upper left). Scale bar = 50 µm.

Figure 1: Quantification of $\alpha_1$-AR staining intensity in normalised units (Z scores) on nerve fibres in the papillary dermis and in large dermal nerve bundles at 4 (A,C) and 28 days (B,D) after PSL. $\alpha_1$-AR staining intensity was quantified in 4 different neuronal populations: all neurons labelled with the pan-neuronal marker TUJ1; peptidergic neurons labelled with CGRP; non-peptidergic neurons labelled with IB4; and myelinated neurons labelled with NF200. * indicates significant differences between ipsilateral (filled circles) and contralateral skin (open circles) and # indicates significant differences between PSL and sham animals (p<0.05). The horizontal bar in each column represents the median.

Figure 2: $\alpha_1$-AR expression (red) was up-regulated in dermal nerve bundles in skin ipsilateral to PSL (A) in comparison to skin contralateral to PSL (D) and that from animals that underwent sham surgery (G). Representative images at 4 days after PSL or sham surgery are shown. Nerve fibres were identified using the pan-neuronal marker TUJ1 (blue; B, E, H). Co-localized images highlight all pixels expressing TUJ1 and a high concentration of $\alpha_1$-AR in white. Scale bar = 50 µm.

Figure 3: Strong $\alpha_1$-AR (red) up-regulation was observed in NF200 labelled fibres (green) in nerve bundles after PSL (A-C) in comparison to those in skin contralateral to PSL (D-F) and after sham surgery (G-I). Representative images at 4 days after PSL or sham surgery are shown. Co-localized images (C, F, I) highlight all pixels that expressed NF200 and a high concentration of $\alpha_1$-AR in white. Scale bar = 50 µm.

Figure 4: Nerve bundle from a skin section at 4 days after PSL stained with triple immunohistochemistry for $\alpha_1$-AR (red), myelin basic protein (MBP; green) and NF200 (blue). Specific axons expressed high levels of $\alpha_1$-AR (A). B shows a merged image of all markers. Co-localization
analysis was then performed identifying pixels containing co-localized MBP and α₁-AR (C) and NF200 and α₁-AR (D). All pixels containing co-localized markers are shown in white in both C and D. Note the minimal co-localisation of α₁-AR with MBP in B and C. Scale bar = 20 μm.

**Figure 5:** α₁-AR expression was up-regulated in IB4 axons in the sciatic nerve at 4 days after PSL (A-D) in comparison to sciatic nerve after sham surgery (E-H). Arrows show axons that are co-labelled with α₁-AR, IB4 and TUJ1, which also have up-regulated expression of α₁-AR. Scale bar = 50 μm.

**Figure 6:** Quantification of α₁-AR staining intensity in normalised units (Z scores) on (A) dermal nerve fibres and (B) in the epidermis of patients with CRPS type II and controls. # α₁-AR expression was greater in the CRPS-affected limb than in controls (p<0.05). The horizontal bar in each column represents the median.

**Figure 7:** α₁-AR expression (red) was up-regulated on dermal nerve fibres (labelled green) in CRPS-affected skin in comparison to nerve fibres from the same patient in unaffected skin and in a representative pain-free control. Nerve fibres were identified using the pan-neuronal marker PGP9.5. Co-localized images highlight all pixels that expressed PGP9.5 and a high concentration of α₁-AR in white. α₁-AR was also expressed in the perineurium surrounding the nerve fibres (red in the co-localized images). Scale bar = 20 μm in the columns illustrating α₁-AR and PGP-9.5 staining of dermal nerve fibres, and 50 μm in images illustrating α₁-AR (red) and PGP-9.5 staining (green) more broadly in the epidermis and dermis. The boxed areas in images in the far-right column show the location of nerve fibres illustrated at higher magnification in the accompanying images.

**Figure 8:** α₁-AR expression (red) was up-regulated in the epidermis in CRPS-affected skin in comparison to pain-free controls. Scale bar = 50 μm.
Table 1. Primary and secondary antibodies used in rat tissues: dilutions and source

<table>
<thead>
<tr>
<th>Antigen and host species</th>
<th>Dilution - skin</th>
<th>Dilution – sciatic nerve</th>
<th>Product code and source</th>
</tr>
</thead>
<tbody>
<tr>
<td>isolectin B4, FITC conjugate</td>
<td>1:250</td>
<td>1:250</td>
<td>L2895, Sigma-Aldrich</td>
</tr>
<tr>
<td><strong>Primary antibodies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>anti α₁-AR, rabbit polyclonal</td>
<td>1:200</td>
<td>1:250</td>
<td>A270, Sigma-Aldrich</td>
</tr>
<tr>
<td>anti neuronal class III β-tubulin (TUJ1), mouse monoclonal</td>
<td>1:800</td>
<td>1:2000</td>
<td>MMS-435P, Covance</td>
</tr>
<tr>
<td>anti CGRP, goat polyclonal</td>
<td>1:400</td>
<td>1:2000</td>
<td>1720-9007, AbD Serotec</td>
</tr>
<tr>
<td>anti NF200, chicken polyclonal</td>
<td>1:4000</td>
<td>1:7500</td>
<td>Jackson ImmunoResearch</td>
</tr>
<tr>
<td>anti MBP, mouse monoclonal</td>
<td>1:400</td>
<td>n/a</td>
<td>Sc-66064, Santa Cruz</td>
</tr>
<tr>
<td>anti SMA, mouse monoclonal</td>
<td>1:4000</td>
<td>n/a</td>
<td>A2547, Sigma-Aldrich</td>
</tr>
<tr>
<td><strong>Secondary antibodies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donkey anti-chicken Cy2</td>
<td>1:600</td>
<td>1:600</td>
<td>Jackson ImmunoResearch</td>
</tr>
<tr>
<td>Donkey anti-goat Dylight-488</td>
<td>1:600</td>
<td>1:600</td>
<td>Jackson ImmunoResearch</td>
</tr>
<tr>
<td>Donkey anti-rabbit Dylight-549</td>
<td>1:1200</td>
<td>1:1200</td>
<td>Jackson ImmunoResearch</td>
</tr>
<tr>
<td>Donkey anti-mouse Dylight-647</td>
<td>1:1000</td>
<td>1:1000</td>
<td>Jackson ImmunoResearch</td>
</tr>
</tbody>
</table>

Abbreviations: α₁-adrenoceptor (α₁-AR), Calcitonin Gene Related Peptide (CGRP), Myelin Basic Protein (MBP), Smooth Muscle Actin (SMA), Neurofilament 200 (NF200), Fluorescein Isothiocyanate (FITC), Cyanine (Cy2).
Table 2. Clinical characteristics of patients with CRPS type II

<table>
<thead>
<tr>
<th>Age, sex</th>
<th>Duration</th>
<th>Injury</th>
<th>Symptoms noted during the physical examination</th>
<th>Effect of regional sympathetic blockade</th>
</tr>
</thead>
<tbody>
<tr>
<td>56, F</td>
<td>10 years</td>
<td>sciatic nerve crush</td>
<td>Allodynia, very swollen, very cold, cyanotic, decreased range of motion</td>
<td>Pain decreased</td>
</tr>
<tr>
<td>48, M</td>
<td>23 months</td>
<td>ulnar nerve laceration</td>
<td>Allodynia, mildly swollen, cold, decreased range of motion, mild dystonia, tremor</td>
<td>Not tried</td>
</tr>
<tr>
<td>45, F</td>
<td>46 months</td>
<td>carpal tunnel surgery</td>
<td>Allodynia, mildly swollen, warm, increased sweating, decreased range of motion, severe dystonia, tremor</td>
<td>Severe nausea</td>
</tr>
<tr>
<td>44, M</td>
<td>6 months</td>
<td>fibula fracture, sural nerve surgery</td>
<td>Allodynia, mildly swollen, cyanotic, decreased range of motion</td>
<td>Not tried</td>
</tr>
<tr>
<td>23, M</td>
<td>6 months</td>
<td>ulnar nerve laceration</td>
<td>Allodynia, mildly swollen, cyanotic, warm, decreased range of motion</td>
<td>No change in pain</td>
</tr>
</tbody>
</table>
Abstract

After peripheral nerve injury, nociceptive afferents acquire an abnormal excitability to adrenergic agents, possibly due to an enhanced expression of $\alpha_1$-adrenoceptors ($\alpha_1$-AR) on these nerve fibres. To investigate this in the present study, changes in $\alpha_1$-AR expression on nerve fibres in the skin and sciatic nerve trunk were assessed using immunohistochemistry in an animal model of neuropathic pain involving partial ligation of the sciatic nerve. In addition, $\alpha_2$-AR expression on nerve fibres was examined in painful and unaffected skin of patients who developed complex regional pain syndrome after a peripheral nerve injury (CRPS type II). Four days after partial ligation of the sciatic nerve, $\alpha_1$-AR expression was greater on dermal nerve fibres that survived the injury than on dermal nerve fibres after sham surgery. This heightened $\alpha_1$-AR expression was observed on non-peptidergic nociceptive afferents in the injured sciatic nerve, dermal nerve bundles and the papillary dermis. Heightened expression of $\alpha_1$-AR in dermal nerve bundles after peripheral nerve injury also co-localised with neurofilament 200, a marker of myelinated nerve fibres. In each patient examined, $\alpha_1$-AR expression was greater on nerve fibres in skin affected by CRPS than in unaffected skin from the same patient or from pain-free controls. Together, these findings provide compelling evidence of an up-regulation of $\alpha_1$-ARs on cutaneous nociceptive afferents after peripheral nerve injury. Activation of these receptors by circulating or locally secreted catecholamines might contribute to chronic pain in CRPS type II.